BIOSURE™ RG Knee Safety & Performance Study

This post-market clinical follow-up (PMCF) study will prospectively evaluate the short-term
(6- and 12-month) safety and performance of the BIOSURE REGENESORB Interference Screw when
used for any of the following:

Knee repair:

- ACL repair Posterior cruciate ligament (PCL) repair

- Extra-capsular repairs

- Medial collateral ligament (MCL)

- Lateral collateral ligament (LCL)

- Posterior oblique ligament (POL)

- Patellar realignment and tendon repairs

- Vastus medialis obliquus advancement

- Iliotibial band tenodesis

Inclusion Criteria:

1. Subject has provided informed consent for study participation.

2. Subject is eighteen (18) years of age or older at the time of enrollment in the study.

3. Subject requires one of the following knee procedures:

- Anterior cruciate ligament (ACL) repair

- Posterior cruciate ligament (PCL) repair

- Extra-capsular repair - Medial collateral ligament (MCL), Lateral collateral
ligament (LCL), Posterior oblique ligament (POL)

- Patellar realignment and tendon repair Vastus medialis obliquus advancement
Iliotibial band tenodesis

4. Subject is willing and able to comply with study visit schedule and to complete study
procedures and questionnaires.

Exclusion Criteria:

1. Subject has Body Mass Index (BMI) > 40.

2. Subject has had total knee arthroplasty (TKA) in the study knee.

3. Subject has conditions that may interfere with graft survival or outcome (e.g. Paget
disease, vascular insufficiency, muscular atrophy, uncontrolled diabetes, moderate to
severe renal insufficiency or neuromuscular disease).

4. Subject has a known allergy to the study device or any of its components.

5. Subject, in the opinion of the Investigator, has an emotional or neurological
condition that would pre-empt their willingness to participate in the study, including
mental illness, mental retardation, drug or alcohol abuse, subject is pregnant, or
plans to become pregnant during the study.

6. Subject is entered in another investigational drug, biologic, or device study, or has
been treated with an investigational product in the past 30 days.

7. Subject is known to be at risk for loss to follow-up or failure to return for
scheduled visits.